Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds

Journal of Immunology

Volumn 190, Issue 12, 2013, Pages 6673-6680

  Lança, Telma ^a   Costa, Maria Fernanda ^b   Gonca̧lves Sousa, Natacha ^a   Rei, Margarida ^a   Grosso, Ana Rita ^a   Penido, Carmen ^b   Silva Santos, Bruno ^a,c  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; CHEMOKINE CCL2; FEMALE; FLOW CYTOMETRY; HUMANS; INFLAMMATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, CCR2; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 84879112769     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300434     Document Type: Article

References (52)

1. Restifo, N. P., M. E. Dudley, and S. A. Rosenberg. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12: 269-281.
2. Hayday, A. C. 2009. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 31: 184-196.
3. Gao, Y., W. Yang, M. Pan, E. Scully, M. Girardi, L. H. Augenlicht, J. Craft, and Z. Yin. 2003. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med. 198: 433-442. (Pubitemid 36976054)
4. Bonneville, M., R. L. O'Brien, and W. K. Born. 2010. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10: 467-478.
5. Thedrez, A., C. Sabourin, J. Gertner, M. C. Devilder, S. Allain-Maillet, J. J. Fournié, E. Scotet, and M. Bonneville. 2007. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol. Rev. 215: 123-135. (Pubitemid 46212235)
6. Correia, D. V., A. Lopes, and B. Silva-Santos. 2013. Tumor cell recognition by γδ T lymphocytes: T-cell receptor vs. NK-cell receptors. OncoImmunology 2: e22892.
7. Girardi, M., D. E. Oppenheim, C. R. Steele, J. M. Lewis, E. Glusac, R. Filler, P. Hobby, B. Sutton, R. E. Tigelaar, and A. C. Hayday. 2001. Regulation of cutaneous malignancy by gammadelta T cells. Science 294: 605-609. (Pubitemid 32999559)
8. Street, S. E., Y. Hayakawa, Y. Zhan, A. M. Lew, D. MacGregor, A. M. Jamieson, A. Diefenbach, H. Yagita, D. I. Godfrey, and M. J. Smyth. 2004. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J. Exp. Med. 199: 879-884. (Pubitemid 38375207)
9. Liu, Z., I. E. Eltoum, B. Guo, B. H. Beck, G. A. Cloud, and R. D. Lopez. 2008. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J. Immunol. 180: 6044-6053.
10. Kabelitz, D., D. Wesch, and W. He. 2007. Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 67: 5-8. (Pubitemid 46142752)
11. Gomes, A. Q., D. S. Martins, and B. Silva-Santos. 2010. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res. 70: 10024-10027.
12. Morita, C. T., C. Jin, G. Sarikonda, and H. Wang. 2007. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2V-delta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol. Rev. 215: 59-76. (Pubitemid 46212230)
13. Hannani, D., Y. Ma, T. Yamazaki, J. Déchanet-Merville, G. Kroemer, and L. Zitvogel. 2012. Harnessing γδ T cells in anticancer immunotherapy. Trends Immunol. 33: 199-206.
14. Viola, A., A. Sarukhan, V. Bronte, and B. Molon. 2012. The pros and cons of chemokines in tumor immunology. Trends Immunol. 33: 496-504.
15. Catellani, S., A. Poggi, A. Bruzzone, P. Dadati, J. L. Ravetti, M. Gobbi, and M. R. Zocchi. 2007. Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood 109: 2078-2085. (Pubitemid 46348208)
16. Maeurer, M. J., D. Martin, W. Walter, K. Liu, L. Zitvogel, K. Halusczcak, H. Rabinowich, R. Duquesnoy, W. Storkus, and M. T. Lotze. 1996. Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J. Exp. Med. 183: 1681-1696. (Pubitemid 26134310)
17. Groh, V., A. Steinle, S. Bauer, and T. Spies. 1998. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279: 1737-1740. (Pubitemid 28164472)
18. Peng, G., H. Y. Wang, W. Peng, Y. Kiniwa, K. H. Seo, and R. F. Wang. 2007. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27: 334-348. (Pubitemid 47284914)
19. Cordova, A., F. Toia, C. La Mendola, V. Orlando, S. Meraviglia, G. Rinaldi, M. Todaro, G. Cicero, L. Zichichi, P. L. Donni, et al. 2012. Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas. PLoS ONE 7: e49878.
20. Donia, M., E. Ellebaek, M. H. Andersen, P. T. Straten, and I. M. Svane. 2012. Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes. OncoImmunology 1: 1297-1304.
21. Correia, D. V., M. Fogli, K. Hudspeth, M. G. da Silva, D. Mavilio, and B. Silva- Santos. 2011. Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 118: 992-1001.
22. Godder, K. T., P. J. Henslee-Downey, J. Mehta, B. S. Park, K. Y. Chiang, S. Abhyankar, and L. S. Lamb. 2007. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 39: 751-757. (Pubitemid 46901973)
23. Lamb, L. S., Jr., P. Musk, Z. Ye, F. van Rhee, S. S. Geier, J. J. Tong, K. M. King, and P. J. Henslee-Downey. 2001. Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant. 27: 601-606. (Pubitemid 32401457)
24. + γδ T-cell migration in allergic reactions: a new "inflammatory" role for the "homeostatic" chemokine CCL25. Eur. J. Immunol. 42: 1097-1101.
25. Kabelitz, D., and D. Wesch. 2003. Features and functions of gamma delta T lymphocytes: focus on chemokines and their receptors. Crit. Rev. Immunol. 23: 339-370. (Pubitemid 38228400)
26. Poggi, A., R. Carosio, D. Fenoglio, S. Brenci, G. Murdaca, M. Setti, F. Indiveri, S. Scabini, E. Ferrero, and M. R. Zocchi. 2004. Migration of V delta 1 and V delta 2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients: competition by HIV-1 Tat. Blood 103: 2205-2213. (Pubitemid 38326239)
27. Brandes, M., K. Willimann, A. B. Lang, K. H. Nam, C. Jin, M. B. Brenner, C. T. Morita, and B. Moser. 2003. Flexible migration program regulates gamma delta T-cell involvement in humoral immunity. Blood 102: 3693-3701. (Pubitemid 37409390)
28. Roth, S. J., T. G. Diacovo, M. B. Brenner, J. P. Rosat, J. Buccola, C. T. Morita, and T. A. Springer. 1998. Transendothelial chemotaxis of human alpha/beta and gamma/delta T lymphocytes to chemokines. Eur. J. Immunol. 28: 104-113. (Pubitemid 28048281)
29. Hayday, A. C. 2000. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 18: 975-1026. (Pubitemid 30365402)
30. Wurbel, M. A., M. Malissen, D. Guy-Grand, E. Meffre, M. C. Nussenzweig, M. Richelme, A. Carrier, and B. Malissen. 2001. Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor gammadelta(+) gut intraepithelial lymphocytes. Blood 98: 2626-2632.
31. Penido, C., M. F. Costa, M. C. Souza, K. A. Costa, A. L. Candéa, C. F. Benjamim, and Md. Henriques. 2008. Involvement of CC chemokines in gammadelta T lymphocyte trafficking during allergic inflammation: the role of CCL2/CCR2 pathway. Int. Immunol. 20: 129-139.
32. Penido, C., A. Vieira-de-Abreu, M. T. Bozza, H. C. Castro-Faria-Neto, and P. T. Bozza. 2003. Role of monocyte chemotactic protein-1/CC chemokine ligand 2 on gamma delta T lymphocyte trafficking during inflammation induced by lipopolysaccharide or Mycobacterium bovis bacille Calmette-Guérin. J. Immunol. 171: 6788-6794. (Pubitemid 37532113)
33. + γδ T lymphocytes during an allergic reaction. Eur. J. Immunol. 42: 1250-1260.
34. Zeng, X., T. A. Moore, M. W. Newstead, J. C. Deng, S. L. Kunkel, A. D. Luster, and T. J. Standiford. 2005. Interferon-inducible protein 10, but not monokine induced by gamma interferon, promotes protective type 1 immunity in murine Klebsiella pneumoniae pneumonia. Infect. Immun. 73: 8226-8236. (Pubitemid 41740312)
35. Dunussi-Joannopoulos, K., K. Zuberek, K. Runyon, R. G. Hawley, A. Wong, J. Erickson, S. Herrmann, and J. P. Leonard. 2002. Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses. Blood 100: 1551-1558. (Pubitemid 34925126)
36. Shields, J. D., I. C. Kourtis, A. A. Tomei, J. M. Roberts, and M. A. Swartz. 2010. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328: 749-752.
37. He, D., H. Li, N. Yusuf, C. A. Elmets, J. Li, J. D. Mountz, and H. Xu. 2010. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J. Immunol. 184: 2281-2288.
38. Curran, M. A., W. Montalvo, H. Yagita, and J. P. Allison. 2010. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 107: 4275-4280.
39. Díaz-Valdés, N., M. Basagoiti, J. Dotor, F. Aranda, I. Monreal, J. I. Riezu-Boj, F. Borrás-Cuesta, P. Sarobe, and E. Feijoó. 2011. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res. 71: 812-821.
40. Lesokhin, A. M., T. M. Hohl, S. Kitano, C. Cortez, D. Hirschhorn-Cymerman, F. Avogadri, G. A. Rizzuto, J. J. Lazarus, E. G. Pamer, A. N. Houghton, et al. 2012. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 72: 876-886.
41. Salomonis, N., B. Nelson, K. Vranizan, A. R. Pico, K. Hanspers, A. Kuchinsky, L. Ta, M. Mercola, and B. R. Conklin. 2009. Alternative splicing in the differentiation of human embryonic stem cells into cardiac precursors. PLOS Comput. Biol. 5: e1000553.
42. Carding, S. R., and P. J. Egan. 2002. Gammadelta T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2: 336-345. (Pubitemid 37328756)
43. Ribot, J. C., A. deBarros, D. J. Pang, J. F. Neves, V. Peperzak, S. J. Roberts, M. Girardi, J. Borst, A. C. Hayday, D. J. Pennington, and B. Silva-Santos. 2009. CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets. Nat. Immunol. 10: 427-436.
44. Mantovani, A., B. Savino, M. Locati, L. Zammataro, P. Allavena, and R. Bonecchi. 2010. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 21: 27-39.
45. Qian, B. Z., J. Li, H. Zhang, T. Kitamura, J. Zhang, L. R. Campion, E. A. Kaiser, L. A. Snyder, and J. W. Pollard. 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222-225.
46. Lu, T., R. Ramakrishnan, S. Altiok, J. I. Youn, P. Cheng, E. Celis, V. Pisarev, S. Sherman, M. B. Sporn, and D. Gabrilovich. 2011. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin. Invest. 121: 4015-4029.
47. Nakasone, Y., M. Fujimoto, T. Matsushita, Y. Hamaguchi, D. L. Huu, M. Yanaba, S. Sato, K. Takehara, and M. Hasegawa. 2012. Host-derived MCP-1 and MIP-1α regulate protective anti-tumor immunity to localized and metastatic B16 melanoma. Am. J. Pathol. 180: 365-374.
48. Williams, P., M. Bouchentouf, M. Rafei, R. Romieu-Mourez, J. Hsieh, M. N. Boivin, S. Yuan, K. A. Forner, E. Birman, and J. Galipeau. 2010. A dendritic cell population generated by a fusion of GM-CSF and IL-21 induces tumor-antigen-specific immunity. J. Immunol. 185: 7358-7366.
49. Molon, B., S. Ugel, F. Del Pozzo, C. Soldani, S. Zilio, D. Avella, A. De Palma, P. Mauri, A. Monegal, M. Rescigno, et al. 2011. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208: 1949-1962.
50. Ma, C., Q. Zhang, J. Ye, F. Wang, Y. Zhang, E. Wevers, T. Schwartz, P. Hunborg, M. A. Varvares, D. F. Hoft, et al. 2012. Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J. Immunol. 189: 5029-5036.
51. Garber, K. 2009. First results for agents targeting cancer-related inflammation. J. Natl. Cancer Inst. 101: 1110-1112.
52. Lança, T., and B. Silva-Santos. 2012. The split nature of tumor-infiltrating leukocytes: implications for cancer surveillance and immunotherapy. OncoImmunology 1: 717-725. do Estado